Belmore Neidrauer successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia, this time involving Apotex.
The Federal Court of Appeal rejected Apotex’s argument that an inducer’s actions must change prescribing practices in order to result in liability for infringement and upheld the trial judge’s finding of infringement.
Link to the case: Apotex Inc v Janssen Inc, 2024 FCA 9
